#United States #Seattle #Nabsys #Electronic Genome Mapping #Hematopathology

Nabsys to Highlight Electronic Genome Mapping Findings at AMP 2026

Nabsys 2.0, LLC, a pioneer in the field of genome mapping, is set to present exciting research at the upcoming Association for Molecular Pathology (AMP) 2026 Annual Meeting. The event will be held from November 10 to 14 in Seattle, Washington, where experts from Augusta University and The University of Texas MD Anderson Cancer Center will showcase their significant findings using Electronic Genome Mapping (EGM) technology.

EGM has emerged as a vital tool in hematopathology for the detection of structural variants associated with blood cancers. Traditional methods like karyotyping, FISH, and chromosomal microarrays, while valuable, often require labor-intensive processes and multiple technologies to characterize hematologic malignancies effectively. In contrast, EGM provides a cohesive, high-resolution approach that streamlines the analysis of structural and copy number variants in a single assay using the innovative Nabsys OhmX™ Platform.

During the Innovation Spotlight Session on November 13, Dr. Ravindra Kolhe, M.D., Ph.D., FCAP, from Augusta University, alongside Dr. Rashmi Kanagal-Shamanna, M.D., from MD Anderson, will present their findings titled "Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies."

Dr. Kolhe emphasizes the importance of understanding structural variants, which play a crucial role in diagnosing and assessing risk for various hematologic malignancies. "Our initial studies demonstrate that EGM can detect all abnormalities found by conventional cytogenetic techniques, while also offering additional molecular insights in complex cases," he noted. This breakthrough could potentially revolutionize cytogenomic analysis and enhance research efficiency in clinical settings.

Dr. Kanagal-Shamanna points out that traditional cytogenetic procedures often rely on invasive bone marrow aspirates, which can lead to procedural complications and limitations in sample quality. “With EGM, we can detect translocations, deletions, and complex rearrangements directly from peripheral blood samples without the need for cell culture, enabling us to achieve a precision that surpasses that of karyotyping,” she explained. Such advancements open new avenues for studying hematologic malignancies, since they allow for less invasive analysis options.

Barrett Bready, M.D., the founder and CEO of Nabsys, believes that collaboration with the hematopathology community is crucial for the future of Electronic Genome Mapping. He asserts that the presentations by Drs. Kolhe and Kanagal-Shamanna at AMP will not only highlight groundbreaking work but also serve as a foundation for building confidence in this innovative technology among clinicians and researchers alike.

At the conference, visitors will have the opportunity to explore Nabsys’s booth (#937) to learn more about the OhmX™ Platform and Nabsys Navigator™, the cloud-based solution for visualizing EGM results. Demonstrations will include SV-Discover™, designed for genome-wide structural variant analysis, and SV-Verify™, which confirms structural variations detected by other methodologies. Additionally, a preview of new software tailored for analyzing hematologic malignancies will be available, allowing attendees to provide feedback on its design and functionality.

EGM technology is strictly for research purposes and is not intended for diagnostic use, underlining the commitment of Nabsys to advance the science of genomics responsibly and ethically.

As this landmark meeting approaches, the research insights shared by Nabsys and esteemed hematopathology experts promise to be transformative in the ongoing quest to enhance clinical outcomes through advanced genetic understanding.